MGB Biopharma and Almac’s Sciences Business Unit have entered into a collaboration where Almac will manufacture the production of their lead gram positive antibacterial compound MGB-BP3.

The compound is a DNA minor groove binder and is currently in pre-clinical development with IND filing targeted for Q3 2012. CEO Dr Miroslav Ravic said “We were very quickly impressed with the approach taken by Almac and they have already shown an intuitive understanding of what it takes to support a small company like ours. We look forward to a continued successful relationship”.

Rick Dyer, VP Operations, Almac further commented “Almac has a wealth of expertise in early phase clinical development and we are delighted to undertake this phase of work for MGB Biopharma and hope this is the first of many successful projects between our companies.”

Following on from their expertise in early phase and steady growth in late phase clinical development, Almac recently announced a capacity expansion within its API facility, further leveraging its API and Drug Product integrated offering. This expansion will allow Almac to continue its commitment to deliver high quality API at competitive prices to its customers.

Notes to Editors

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS^® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.

The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new North American Headquarters located in Souderton PA.